Larvol Delta - Acumen-Pharmaceuticals-Completes-Enrollment-of-ALTITUDEAD-a-Phase-2-Clinical-Trial-of-Sabirnetug-ACU193-in-Early-Alzheimers-Disease

sabirnetug IV (ACU193 IV) - Acumen Pharma

https://www.globenewswire.com/news-release/2025/03/26/3049613/0/en/Acumen-Pharmaceuticals-Completes-Enrollment-of-ALTITUDE-AD-a-Phase-2-Clinical-Trial-of-Sabirnetug-ACU193-in-Early-Alzheimer-s-Disease.html

Mar 26, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next